SG Americas Securities LLC Purchases 15,089 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

SG Americas Securities LLC boosted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 444.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 18,486 shares of the company's stock after buying an additional 15,089 shares during the period. SG Americas Securities LLC's holdings in IDEAYA Biosciences were worth $475,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. State Street Corp grew its stake in shares of IDEAYA Biosciences by 15.4% in the third quarter. State Street Corp now owns 3,317,936 shares of the company's stock valued at $105,112,000 after buying an additional 443,640 shares in the last quarter. Barclays PLC raised its holdings in IDEAYA Biosciences by 188.8% in the 3rd quarter. Barclays PLC now owns 181,170 shares of the company's stock valued at $5,739,000 after acquiring an additional 118,438 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in IDEAYA Biosciences by 12.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 689,073 shares of the company's stock worth $21,830,000 after purchasing an additional 78,518 shares during the period. Verition Fund Management LLC acquired a new position in IDEAYA Biosciences during the third quarter valued at approximately $246,000. Finally, General American Investors Co. Inc. bought a new position in IDEAYA Biosciences in the third quarter valued at about $2,851,000. Institutional investors and hedge funds own 98.29% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IDYA. Leerink Partners cut shares of IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $41.00 to $27.00 in a research report on Tuesday, November 5th. UBS Group began coverage on shares of IDEAYA Biosciences in a research note on Thursday, October 24th. They issued a "buy" rating and a $50.00 price objective on the stock. Royal Bank of Canada restated an "outperform" rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Wedbush reiterated an "outperform" rating and set a $52.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Finally, Leerink Partnrs lowered IDEAYA Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, IDEAYA Biosciences currently has an average rating of "Moderate Buy" and a consensus target price of $53.67.

IDEAYA Biosciences Price Performance

Shares of IDYA traded up $0.99 during trading hours on Wednesday, hitting $25.10. The company's stock had a trading volume of 673,134 shares, compared to its average volume of 859,923. The business has a 50 day simple moving average of $25.12 and a two-hundred day simple moving average of $30.92. IDEAYA Biosciences, Inc. has a 52-week low of $22.10 and a 52-week high of $47.74. The company has a market cap of $2.17 billion, a price-to-earnings ratio of -10.77 and a beta of 0.82.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.63) by $0.03. During the same period in the prior year, the company posted ($0.46) EPS. Research analysts predict that IDEAYA Biosciences, Inc. will post -2.45 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.